ANC 0 3 0 3 B-clinical_variable
> 4 5 4 5 O
1000 5 9 5 9 B-lower_bound

Age 0 3 10 13 B-age
> 4 5 14 15 O
18 6 8 16 18 B-lower_bound
years 9 14 19 24 I-lower_bound

Definition 0 10 25 35 O
includes 11 19 36 44 O
subjects 20 28 45 53 O
who 29 32 54 57 O
meet 33 37 58 62 O
the 38 41 63 66 O
ACR 42 45 67 70 O
criteria 46 54 71 79 O
for 55 58 80 83 O
scleroderma 59 70 84 95 B-chronic_disease

FVC 0 3 96 99 B-clinical_variable
< 4 5 100 101 O
40 6 8 102 104 B-upper_bound
% 8 9 104 105 I-upper_bound
or 10 12 106 108 O
DLCO 13 17 109 113 B-clinical_variable
< 18 19 114 115 O
30 19 21 115 117 B-upper_bound
% 21 22 117 118 I-upper_bound
predicted 23 32 119 128 O

Fall 0 4 129 133 O
in 5 7 134 136 O
FVC 8 11 137 140 B-clinical_variable
> 12 13 141 142 O
10 14 16 143 145 B-lower_bound
% 16 17 145 146 I-lower_bound
over 18 22 147 151 O
6 23 24 152 153 B-upper_bound
months 25 31 154 160 I-upper_bound
on 32 34 161 163 O
at 35 37 164 166 O
least 38 43 167 172 O
12 44 46 173 175 B-lower_bound
months 47 53 176 182 I-lower_bound
of 54 56 183 185 O
prior 57 62 186 191 B-treatment
therapy 63 70 192 199 I-treatment

Fall 0 4 200 204 O
in 5 7 205 207 O
FVC 8 11 208 211 B-clinical_variable
> 12 13 212 213 O
10 14 16 214 216 B-lower_bound
% 16 17 216 217 I-lower_bound
over 18 22 218 222 O
the 23 26 223 226 O
preceding 27 36 227 236 B-upper_bound
12 37 39 237 239 I-upper_bound
months 40 46 240 246 I-upper_bound
or 47 49 247 249 O
less 50 54 250 254 O
in 55 57 255 257 O
the 58 61 258 261 O
absence 62 69 262 269 O
of 70 72 270 272 O
prior 73 78 273 278 B-treatment
therapy 79 86 279 286 I-treatment
or 87 89 287 289 O
another 90 97 290 297 O
identified 98 108 298 308 O
causative 109 118 309 318 O
process 119 126 319 326 O
as 127 129 327 329 O
assessed 130 138 330 338 O
by 139 141 339 341 O
the 142 145 342 345 O
primary 146 153 346 353 O
scleroderma 154 165 354 365 B-treatment
physician 166 175 366 375 O

Female 0 6 376 382 B-gender
subject 7 14 383 390 I-gender
is 15 17 391 393 O
either 18 24 394 400 O
post 25 29 401 405 O
- 29 30 405 406 O
menopausal 30 40 406 416 O
or 41 43 417 419 O
surgically 44 54 420 430 O
sterilized 55 65 431 441 O
or 66 68 442 444 O
willing 69 76 445 452 B-contraception_consent
to 77 79 453 455 I-contraception_consent
use 80 83 456 459 I-contraception_consent
an 84 86 460 462 I-contraception_consent
acceptable 87 97 463 473 I-contraception_consent
method 98 104 474 480 I-contraception_consent
of 105 107 481 483 I-contraception_consent
birth 108 113 484 489 I-contraception_consent
control 114 121 490 497 I-contraception_consent
( 122 123 498 499 O
i.e. 123 127 499 503 O
, 127 128 503 504 O
a 129 130 505 506 O
hormonal 131 139 507 515 B-contraception_consent
contraceptive 140 153 516 529 I-contraception_consent
, 153 154 529 530 O
intra 155 160 531 536 B-contraception_consent
- 160 161 536 537 I-contraception_consent
uterine 161 168 537 544 I-contraception_consent
device 169 175 545 551 I-contraception_consent
, 175 176 551 552 O
diaphragm 177 186 553 562 B-contraception_consent
with 187 191 563 567 I-contraception_consent
spermicide 192 202 568 578 I-contraception_consent
, 202 203 578 579 O
condom 204 210 580 586 B-contraception_consent
with 211 215 587 591 I-contraception_consent
spermicide 216 226 592 602 I-contraception_consent
, 226 227 602 603 O
or 228 230 604 606 O
abstinence 231 241 607 617 B-contraception_consent
) 241 242 617 618 O
for 243 246 619 622 O
the 247 250 623 626 O
duration 251 259 627 635 O
of 260 262 636 638 O
the 263 266 639 642 O
study 267 272 643 648 O

Female 0 6 649 655 B-gender
subject 7 14 656 663 I-gender
is 15 17 664 666 O
pregnant 18 26 667 675 B-pregnancy

If 0 2 676 678 O
first 3 8 679 684 O
non 9 12 685 688 O
- 12 13 688 689 O
Raynaud 13 20 689 696 B-clinical_variable
's 20 22 696 698 I-clinical_variable
manifestation 23 36 699 712 I-clinical_variable
of 37 39 713 715 I-clinical_variable
SSc 40 43 716 719 I-clinical_variable
< 44 45 720 721 O
36 46 48 722 724 B-upper_bound
months 49 55 725 731 I-upper_bound
, 55 56 731 732 O
then 57 61 733 737 O
if 62 64 738 740 O
any 65 68 741 744 O
of 69 71 745 747 O
the 72 75 748 751 O
following 76 85 752 761 O
are 86 89 762 765 O
true 90 94 766 770 O
: 94 95 770 771 O
FVC 96 99 772 775 B-clinical_variable
< 100 101 776 777 O
70 101 103 777 779 B-upper_bound
% 103 104 779 780 I-upper_bound
predicted 105 114 781 790 O
or 115 117 791 793 O
HRCT 118 122 794 798 B-clinical_variable
Fibmax 123 129 799 805 I-clinical_variable
> 130 131 806 807 O
3 131 132 807 808 O
or 133 135 809 811 O
FVC 136 139 812 815 O
< 140 141 816 817 O
85 142 144 818 820 B-upper_bound
% 144 145 820 821 I-upper_bound
and 146 149 822 825 O
MRSS 150 154 826 830 B-clinical_variable
increase 155 163 831 839 O
> 164 165 840 841 O
5 166 167 842 843 O
over 168 172 844 848 B-upper_bound
6 173 174 849 850 I-upper_bound
months 175 181 851 857 I-upper_bound
Regardless 182 192 858 868 O
of 193 195 869 871 O
disease 196 203 872 879 O
duration 204 212 880 888 O

Male 0 4 889 893 B-gender
subject 5 12 894 901 O
agrees 13 19 902 908 B-contraception_consent
to 20 22 909 911 I-contraception_consent
use 23 26 912 915 I-contraception_consent
an 27 29 916 918 I-contraception_consent
acceptable 30 40 919 929 I-contraception_consent
method 41 47 930 936 I-contraception_consent
for 48 51 937 940 I-contraception_consent
contraception 52 65 941 954 I-contraception_consent
for 66 69 955 958 O
the 70 73 959 962 O
duration 74 82 963 971 O
of 83 85 972 974 O
the 86 89 975 978 O
study 90 95 979 984 O

Meet 0 4 985 989 O
established 5 16 990 1001 O
criteria 17 25 1002 1010 O
for 26 29 1011 1014 O
diffuse 30 37 1015 1022 O
or 38 40 1023 1025 O
limited 41 48 1026 1033 O
SSc 49 52 1034 1037 B-cancer
and 53 56 1038 1041 O
evidence 57 65 1042 1050 O
of 66 68 1051 1053 O
pulmonary 69 78 1054 1063 O
at 79 81 1064 1066 O
high 82 86 1067 1071 O
risk 87 91 1072 1076 O
of 92 94 1077 1079 O
progression 95 106 1080 1091 O
with 107 111 1092 1096 O
or 112 114 1097 1099 O
without 115 122 1100 1107 O
progressive 123 134 1108 1119 O
skin 135 139 1120 1124 B-chronic_disease
disease 140 147 1125 1132 I-chronic_disease

Myocardial 0 10 1133 1143 B-chronic_disease
infarction 11 21 1144 1154 I-chronic_disease
within 22 28 1155 1161 O
6 29 30 1162 1163 B-upper_bound
months 31 37 1164 1170 I-upper_bound
prior 38 43 1171 1176 I-upper_bound
to 44 46 1177 1179 O
enrollment 47 57 1180 1190 O
or 58 60 1191 1193 O
has 61 64 1194 1197 O
New 65 68 1198 1201 B-clinical_variable
York 69 73 1202 1206 I-clinical_variable
Heart 74 79 1207 1212 I-clinical_variable
Association 80 91 1213 1224 I-clinical_variable
( 92 93 1225 1226 I-clinical_variable
NYHA 93 97 1226 1230 I-clinical_variable
) 97 98 1230 1231 I-clinical_variable
Class 99 104 1232 1237 B-lower_bound
III 105 108 1238 1241 I-lower_bound
or 109 111 1242 1244 O
IV 112 114 1245 1247 B-upper_bound
heart 115 120 1248 1253 B-chronic_disease
failure 121 128 1254 1261 I-chronic_disease
, 128 129 1261 1262 O
uncontrolled 130 142 1263 1275 B-chronic_disease
angina 143 149 1276 1282 I-chronic_disease
, 149 150 1282 1283 O
severe 151 157 1284 1290 O
uncontrolled 158 170 1291 1303 O
ventricular 171 182 1304 1315 B-chronic_disease
arrhythmias 183 194 1316 1327 I-chronic_disease
, 194 195 1327 1328 O
or 196 198 1329 1331 O
electrocardiographic 199 219 1332 1352 B-treatment
evidence 220 228 1353 1361 O
of 229 231 1362 1364 O
acute 232 237 1365 1370 O
ischemia 238 246 1371 1379 O
or 247 249 1380 1382 O
active 250 256 1383 1389 O
conduction 257 267 1390 1400 B-chronic_disease
system 268 274 1401 1407 I-chronic_disease
abnormalities 275 288 1408 1421 I-chronic_disease
. 288 289 1421 1422 O
Prior 290 295 1423 1428 O
to 296 298 1429 1431 O
study 299 304 1432 1437 O
entry 305 310 1438 1443 O
, 310 311 1443 1444 O
any 312 315 1445 1448 O
ECG 316 319 1449 1452 O
abnormality 320 331 1453 1464 O
at 332 334 1465 1467 O
Screening 335 344 1468 1477 O
has 345 348 1478 1481 O
to 349 351 1482 1484 O
be 352 354 1485 1487 O
documented 355 365 1488 1498 O
by 366 368 1499 1501 O
the 369 372 1502 1505 O
investigator 373 385 1506 1518 O
as 386 388 1519 1521 O
not 389 392 1522 1525 O
medically 393 402 1526 1535 O
relevant 403 411 1536 1544 O

No 0 2 1545 1547 O
evidence 3 11 1548 1556 O
of 12 14 1557 1559 O
acute 15 20 1560 1565 O
infection 21 30 1566 1575 B-chronic_disease

Patient 0 7 1576 1583 O
has 8 11 1584 1587 O
Grade 12 17 1588 1593 B-chronic_disease
2 18 19 1594 1595 I-chronic_disease
peripheral 20 30 1596 1606 I-chronic_disease
neuropathy 31 41 1607 1617 I-chronic_disease
by 42 44 1618 1620 O
history 45 52 1621 1628 O
within 53 59 1629 1635 O
14 60 62 1636 1638 B-upper_bound
days 63 67 1639 1643 I-upper_bound
before 68 74 1644 1650 I-upper_bound
enrollment 75 85 1651 1661 O

Patient 0 7 1662 1669 O
has 8 11 1670 1673 O
a 12 13 1674 1675 O
calculated 14 24 1676 1686 O
or 25 27 1687 1689 O
measured 28 36 1690 1698 B-clinical_variable
creatinine 37 47 1699 1709 I-clinical_variable
clearance 48 57 1710 1719 I-clinical_variable
of 58 60 1720 1722 O
< 61 62 1723 1724 O
20 63 65 1725 1727 B-upper_bound
ml 66 68 1728 1730 I-upper_bound
/ 68 69 1730 1731 I-upper_bound
minute 69 75 1731 1737 I-upper_bound
within 76 82 1738 1744 O
14 83 85 1745 1747 B-upper_bound
days 86 90 1748 1752 I-upper_bound
before 91 97 1753 1759 I-upper_bound
enrollment 98 108 1760 1770 O

Patient 0 7 1771 1778 O
has 8 11 1779 1782 O
a 12 13 1783 1784 O
platelet 14 22 1785 1793 B-clinical_variable
count 23 28 1794 1799 I-clinical_variable
of 29 31 1800 1802 O
less 32 36 1803 1807 O
than 37 41 1808 1812 O
50,000 42 48 1813 1819 B-upper_bound
within 49 55 1820 1826 O
14 56 58 1827 1829 B-upper_bound
days 59 63 1830 1834 I-upper_bound
before 64 70 1835 1841 I-upper_bound
enrollment 71 81 1842 1852 O

Patient 0 7 1853 1860 O
has 8 11 1861 1864 O
an 12 14 1865 1867 O
absolute 15 23 1868 1876 B-clinical_variable
neutrophil 24 34 1877 1887 I-clinical_variable
count 35 40 1888 1893 I-clinical_variable
of 41 43 1894 1896 O
less 44 48 1897 1901 O
1000 49 53 1902 1906 B-upper_bound
within 54 60 1907 1913 O
14 61 63 1914 1916 B-upper_bound
days 64 68 1917 1921 I-upper_bound
before 69 75 1922 1928 I-upper_bound
enrollment 76 86 1929 1939 O

Patient 0 7 1940 1947 O
has 8 11 1948 1951 O
hypersensitivity 12 28 1952 1968 O
to 29 31 1969 1971 O
bortezomib 32 42 1972 1982 B-allergy_name
, 42 43 1982 1983 O
boron 44 49 1984 1989 B-allergy_name
or 50 52 1990 1992 O
mannitol 53 61 1993 2001 B-allergy_name

Patient 0 7 2002 2009 O
has 8 11 2010 2013 O
received 12 20 2014 2022 O
other 21 26 2023 2028 O
investigational 27 42 2029 2044 B-treatment
drugs 43 48 2045 2050 I-treatment
within 49 55 2051 2057 O
4 56 57 2058 2059 B-upper_bound
weeks 58 63 2060 2065 I-upper_bound
before 64 70 2066 2072 I-upper_bound
enrollment 71 81 2073 2083 O

Platelets 0 9 2084 2093 B-clinical_variable
> 10 11 2094 2095 O
75,000 11 17 2095 2101 B-lower_bound

Psychiatric 0 11 2102 2113 B-chronic_disease
illness 12 19 2114 2121 I-chronic_disease
likely 20 26 2122 2128 O
to 27 29 2129 2131 O
interfere 30 39 2132 2141 O
with 40 44 2142 2146 O
participation 45 58 2147 2160 O
in 59 61 2161 2163 O
this 62 66 2164 2168 O
clinical 67 75 2169 2177 O
study 76 81 2178 2183 O

Serious 0 7 2184 2191 O
medical 8 15 2192 2199 O
co 16 18 2200 2202 B-chronic_disease
- 18 19 2202 2203 I-chronic_disease
morbidity 19 28 2203 2212 I-chronic_disease
which 29 34 2213 2218 O
in 35 37 2219 2221 O
the 38 41 2222 2225 O
opinion 42 49 2226 2233 O
of 50 52 2234 2236 O
the 53 56 2237 2240 O
investigator 57 69 2241 2253 O
makes 70 75 2254 2259 O
participation 76 89 2260 2273 O
in 90 92 2274 2276 O
the 93 96 2277 2280 O
study 97 102 2281 2286 O
too 103 106 2287 2290 O
high 107 111 2291 2295 O
risk 112 116 2296 2300 O

Stable 0 6 2301 2307 O
MMF 7 10 2308 2311 B-treatment
dose 11 15 2312 2316 O
for 16 19 2317 2320 O
16 20 22 2321 2323 B-upper_bound
weeks 23 28 2324 2329 I-upper_bound

Willingness 0 11 2330 2341 O
to 12 14 2342 2344 O
discontinue 15 26 2345 2356 O
present 27 34 2357 2364 O
therapy 35 42 2365 2372 B-treatment
for 43 46 2373 2376 O
the 47 50 2377 2380 O
duration 51 59 2381 2389 O
of 60 62 2390 2392 O
the 63 66 2393 2396 O
study 67 72 2397 2402 O

